Neuroone Medical Technologies
High-definition, minimally invasive devices revolutionizing epilepsy diagnosis and treatment with thin film electrode technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $8.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (91 %) | (4 %) | 1041 % | 77 % | 152 % | 42 % | 41 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5538 %) | (5773 %) | (612 %) | (333 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5584 %) | (5842 %) | (607 %) | (357 %) | (60 %) | (63 %) | (34 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2203 % | 2880 % | 355 % | 147 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
NeuroOne Medical Technologies Corp. is a publicly traded company focused on developing high-definition, minimally invasive diagnostic and treatment devices using proprietary thin film electrode technology. The company's primary market is the neurostimulation device sector, with an initial focus on epilepsy. NeuroOne serves healthcare providers and institutions specializing in neurological disorders. The business model revolves around the commercialization of its innovative medical devices, generating revenue through sales and partnerships with leading medical institutions. NeuroOne's growth strategy is supported by strong validation from top-tier institutions and a world-class leadership team. The company has already presented promising evidence at the American Epilepsy Society, indicating significant improvements in surgical treatments.
Keywords: epilepsy, neurostimulation, thin film electrodes, minimally invasive, diagnostic devices, treatment devices, medical technology, healthcare, neurological disorders, commercialization.